James W Hodge

24PUBLICATIONS
44CO-AUTHORS
Molecular targetsEpidemiological modellingCancer cell biologyCancer therapy (excl. chemotherapy and radiation therapy)Innate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Jul 01, 2026
PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression.

|Dec 19, 2025
The ATR inhibitor tuvusertib (M1774) sensitizes prostate carcinoma to natural killer cell-mediated cytotoxicity, which is further augmented by the IL-15 receptor superagonist N-803.

Cailyn A Lee, Jeffrey Schlom, James W Hodge

|Dec 12, 2025
Hypoxia-induced EGR1 remodels neutrophils to suppress antitumor immunity.

Tian-Gen Chang, Jay Friedman, Paul E Clavijo

|Nov 07, 2025
TIME for Endometrial Cancer: Advancements and Challenges in Therapeutic Targets for the Endometrial Cancer Tumor Immune Microenvironment.

Margaret R Pruitt, Kellsye P Fabian, Jung-Min Lee

|Oct 28, 2025
Combination of a novel TCR Vβ chain-directed selective T cell activator with standard of care therapy for head and neck cancer improves antitumor responses and promotes regression of checkpoint-refractory tumor models.

Francesca Rosato, Ginette Santiago-Sanchez, Kellsye P Fabian

|Oct 24, 2024
Alum-anchored IL-12 combined with cytotoxic chemotherapy and immune checkpoint blockade enhanced antitumor immune responses in head and neck cancer models.

Kellsye P Fabian, Ginette Santiago-Sanchez, Michelle R Padget

Pageof 4

Frequent Collaborators

11 joint publications

Kellsye P Fabian

9 joint publications

Jeffrey Schlom

4 joint publications

Ginette Santiago-Sánchez

4 joint publications

Clint Tanner Allen